title: VP-16 and adriamycin in patients with advanced breast cancer.
abstract: Twenty-eight patients with advanced adenocarcinoma of the breast were treated with a combination of VP-16 and adriamycin (VAD). Two complete (CR), and eight partial (PR) remissions were observed. The CR plus PR produced a 36% response rate in this study. Nine additional patients had stable disease for at least 2 months. No drug deaths were seen with this combination, but thrombocytopenia, leukopenia, and vomiting were observed. Alopecia was seen in 100% of the patients treated with the above combination. This study suggests that the combination of adriamycin and VP-16 may be a good second-line therapy for patients with adenocarcinoma of the breast who failed and/or relapsed to CMFVP.
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D011241:Prednisone / Q000008:administration & dosage; D013921:Thrombocytopenia / Q000139:chemically induced; D014750:Vincristine / Q000008:administration & dosage; D014839:Vomiting / Q000139:chemically induced
chemical_list: D014750:Vincristine; D005047:Etoposide; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D011034:Podophyllotoxin; D005472:Fluorouracil; D011241:Prednisone; D008727:Methotrexate